As of September 26, 2026, Iambic Therapeutics is reported to have filed for an initial public offering on Nasdaq, per Reuters and MobiHealthNews, but it has not confirmed a listing date. Reuters reported on September 21, 2026, a Monday, that the Nvidia and Qatar Investment Authority backed AI drug discovery company filed for a US IPO under the proposed ticker IAM, as part of a broader wave of biotech IPO filings; MobiHealthNews confirmed the filing separately on September 23, 2026. Iambic's lead candidate, IAM1363, is a HER2 targeted small molecule inhibitor being studied in an open label Phase 1/1b dose escalation and optimization trial for solid tumors including breast cancer, according to public clinical trial records; it has not yet reached a registrational, or pivotal, trial. Company reporting has described plans to use IPO proceeds to advance IAM1363, though the specific claim that proceeds are earmarked to move it toward a registrational trial could not be independently confirmed from the sources reviewed here and should be treated as unconfirmed company guidance rather than a verified fact. A public S-1 has not been reviewed directly on SEC EDGAR as part of this summary; track EDGAR and Iambic's own site directly for filing updates, not secondary reporting alone.
segmara.com publishes educational private-market context and can route limited interest into account-based private follow-up. Public pages do not create an offer, allocation, payment instruction, investment advice, or issuer-affiliated workflow.
Key points
A Nasdaq filing, not a listing date
Reuters reported on September 21, 2026, a Monday, that Iambic Therapeutics filed for an initial public offering on Nasdaq under the proposed ticker IAM. The report described Iambic as an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, and framed the filing as part of a broader wave of biotech companies moving toward US listings. MobiHealthNews confirmed the filing separately on September 23, 2026.
A filing is the start of the IPO process, not its end. Neither source reviewed for this page reports a listing date, a share price range, or a completed registration; a public S-1 has not been independently reviewed on SEC EDGAR as part of this summary.
What IAM1363 actually is, and where it stands
Iambic's lead candidate, IAM1363, is a HER2 targeted small molecule inhibitor, active against both wildtype HER2 and the exon 20 mutant form, being developed for solid tumors including breast cancer. That description is supported by public clinical trial records, including a ClinicalTrials.gov listing, NCT06253871, and abstracts presented at ASCO and published in Annals of Oncology.
Those same records show IAM1363 is currently in an open label Phase 1/1b dose escalation and optimization study. That is an early, dose finding stage, not a registrational, or pivotal, trial, the later stage typically used to support a marketing application.
What the filing does and does not confirm about use of proceeds
Reporting on the filing has described Iambic's plans to use IPO proceeds to advance IAM1363, in some cases framing that as moving the candidate toward a registrational trial. That specific framing could not be independently confirmed from the Reuters coverage or from the public trial registry and abstract evidence checked for this page, and should be read as company guidance rather than a verified fact.
For the primary filing itself, including any stated use of proceeds in the company's own words, check SEC EDGAR directly; this page has not independently reviewed the S-1 or F-1 filing text there.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-iambic-therapeutics-ipo
Stable URL path for AI and search extraction.
Article title
When Will Iambic Therapeutics IPO? It Filed for Nasdaq Under IAM
Main page topic.
Attached public sources
2
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Request-quote listings
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Catalogue breadth100%
51 public listings
Visible pricing coverage72%
37 of 51 listings show a mark
Source depth48%
2 source links
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Catalogue breadth
100 / 100
51 public listings
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Source depth
48 / 100
2 source links
Analytical lens
Search intent
The search behind 'When Will Iambic Therapeutics IPO? It Filed for Nasdaq Under IAM' is an access-intent query. People want to know where they can start interest in Iambic Therapeutics private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover private markets categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How private-share access starts on Segmara
Reuters reported on September 21, 2026, a Monday, that Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed for a Nasdaq IPO under the proposed ticker IAM, part of a broader wave of biotech IPO filings; MobiHealthNews confirmed the filing on September 23, 2026.
Iambic's lead candidate, IAM1363, is a HER2 targeted small molecule inhibitor for solid tumors including breast cancer that is currently in an open label Phase 1/1b dose escalation and optimization study, not yet a registrational, or pivotal, trial, per public clinical trial records including ClinicalTrials.gov listing NCT06253871 and ASCO and Annals of Oncology abstracts.
Company reporting frames IPO proceeds as intended to advance IAM1363, but the specific claim that proceeds would move it toward a registrational trial is not independently confirmed by the Reuters coverage or by the public trial registry evidence reviewed for this page.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Segmara Pro sends a weekly Pipeline Brief and an alert the day a covered company's filing goes public or is first publicly reported, across 60+ private tech companies. $15 a month, cancel anytime.
Can retail investors track private-company shares on Segmara?
Yes. Visitors can start with the free Iambic Therapeutics tracker using email only, then decide whether a private follow-up makes sense. Availability, eligibility, pricing, allocation, transfer approval, documents, and final terms can still vary by route.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: visitors can follow named private-company interest before any account, document upload, or payment step.
What is the easiest next step?
Open the free Iambic Therapeutics tracker first. It is email-only and keeps the public step narrow while final availability, pricing, eligibility, and terms are handled only through private follow-up.
Has Iambic Therapeutics confirmed an IPO date?
No. Reuters reported on September 21, 2026 that Iambic Therapeutics filed for a Nasdaq IPO under the proposed ticker IAM. A filing is a step toward going public, not a confirmed listing date, and no specific date appears in the sources reviewed here.
Who is backing Iambic Therapeutics?
Reuters described Iambic as backed by Nvidia and the Qatar Investment Authority, QIA, in its September 21, 2026 report on the Nasdaq filing. No other investor names appear in the sources reviewed for this page.
What stage is Iambic's lead drug candidate in?
IAM1363, described as a HER2 targeted small molecule inhibitor for solid tumors including breast cancer, is in an open label Phase 1/1b dose escalation and optimization study, according to public clinical trial records and ASCO and Annals of Oncology abstracts. It has not reached a registrational, or pivotal, trial.
Can I buy Iambic Therapeutics shares before the IPO?
Not through a public exchange. Iambic has filed for an IPO but has not completed a listing, and Segmara does not sell, broker, or arrange purchases of Iambic Therapeutics shares. Check SEC EDGAR directly for the company's public filings.
Next step
Track private-market prices free.
If this article helped explain Iambic Therapeutics, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account, and no allocation promise.
When a full account makes sense, Segmara can route limited interest into an account-based private follow-up. Availability, pricing, eligibility, allocation, transfer approval, liquidity, and final terms can vary by company and route.